Compare CGEM & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | WGO |
|---|---|---|
| Founded | 2016 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 929.1M |
| IPO Year | 2020 | 1994 |
| Metric | CGEM | WGO |
|---|---|---|
| Price | $16.13 | $29.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $30.13 | ★ $42.78 |
| AVG Volume (30 Days) | ★ 956.5K | 572.3K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | N/A | ★ 106.82 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $1,985,674,000.00 |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | $5.20 | $4.69 |
| P/E Ratio | ★ N/A | $84.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $27.64 |
| 52 Week High | $16.74 | $50.16 |
| Indicator | CGEM | WGO |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 43.28 |
| Support Level | $11.92 | $28.56 |
| Resistance Level | N/A | $35.01 |
| Average True Range (ATR) | 1.03 | 1.26 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 89.05 | 48.92 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.